F-Star Therapeutics and Sino Biopharmaceutical Seek CFIUS Approval with Extended Deadline
The acquisition of UK-based biologics firm F-Star Therapeutics (NASDAQ: FSTX) by China’s Sino Biopharmaceutical (HKG:...
Company
Jiangsu Hengrui’s SHR8058 Accepted for Review by China’s NMPA for Dry Eye Disease
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that its market filing for the drug...
Nanjing-Based Frontier Biotechnologies Secures Full Approval for Albuvirtide in China
Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary approval filing for albuvirtide, China’s first...
Junshi Biosciences’ JS401 Accepted for Review by China’s NMPA for Hyperlipidemia
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the National Medical Products Administration...
Pfizer Reports Record Revenues as COVID-19 Sales Soar; 2023 Guidance Amid Market Shifts
US-based Pfizer Inc. (NYSE: PFE) reported its Q4 2022 financial results, highlighting an all-time high...
Junshi Biosciences Partners with Huahai for Production of COVID-19 Drug VV116
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a production and supply agreement between...
Ocumension Completes Enrollment for Global Phase III Study of Myopia Treatment OT-101
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced the completion of enrollment for a...
R&B Bio Raises RMB 200 Million in Series A+ Round to Advance Gene Therapy Pipeline
Chengdu-based gene therapy firm R&B Biotech has reportedly secured over RMB 200 million (USD 29.64...
Hengrui’s HER2-Targeted ADC SHR-A1811 Gains NMPA Clearance for Clinical Trial
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clearance from the National Medical Products...
Hengrui’s Lutetium [177Lu] Oxy-Octreotide Gains Clinical Clearance in China
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical clearance from the National Medical...
Changchun BCHT Gains NMPA Approval for Herpes Zoster Vaccine
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced receiving marketing approval from the...
Jemincare’s Avatrombopag Market Filing Accepted for Review by China’s CDE
China-based Jiangxi Jemincare Group has announced that its market filing for avatrombopag maleate (20mg) has...
Ascletis Receives FDA Approval for Phase IIa Trial of ASC10 in RSV Infection
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving approval from the US FDA to...
Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development
South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals...
Sirnaomics Accelerates STP705 Development After Positive Skin Cancer Trial Results
Sirnaomics Ltd (HKG: 2257) is advancing the clinical development of STP705 following positive results from...
Betta Pharmaceuticals Gains FDA Approval for Clinical Trial of BPI-460372
China’s Betta Pharmaceuticals (SHE: 300558) has announced receiving clinical trial approval from the US FDA...
Novartis Q4 Results Show Growth in Innovative Medicines Amid Sandoz Spin-Off Plans
Swiss pharmaceutical giant Novartis (NYSE: NVS) has released its financial results for Q4 and the...
Zhifei Renews Vaccine Supply Agreement with Merck Sharp & Dohme
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the renewal of a supply,...
Abbott’s Q4 Sales Dip Amid COVID-19 Testing Decline, China Market Updates
US-based Abbott (NYSE: ABT) released its Q4 2022 financial results last week, showing a 6.1%...
Kelun’s SKB264 Receives Breakthrough Therapy Designation for Lung Cancer
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody-drug conjugate (ADC) SKB264,...